Company Overview of Okairos AG
Okairos AG operates as a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of T-cell based vaccines for infectious diseases and cancer. It focuses on developing vaccines for hepatitis C virus, malaria, HIV, respiratory syncytial virus, and influenza, as well as cancer. The company was founded in 2007 and is headquartered in Basel, Switzerland with laboratories in Rome and Naples, Italy. As of May 29, 2013, Okairos AG operates as a subsidiary of GlaxoSmithKline plc.
Founded in 2007
41 61 270 35 35
41 61 270 35 00
Key Executives for Okairos AG
Okairos AG Key Developments
Similar Private Companies By Industry
|JRS Rettenmaier AG||Europe|
|ACIC Europe Limited||Europe|
|Amal Therapeutics SA||Europe|
|Cilag GmbH International||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Okairos AG, please visit www.okairos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.